[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507943":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":22,"responsibleParty":36,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"RADIATION","Whole breast irradiation +\u002F- tumor bed boost","Postoperative whole breast irradiation (3D-conformal radiation therapy or IMRT) with or without tumor bed boost (sequential or simultaneous integrated boost)",[14],{"name":15,"affiliation":5,"role":16},"Haeyoung Kim, MD, PhD","PRINCIPAL_INVESTIGATOR",[18],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","82-2-3410-2612","haeyoung0131.kim@samsung.com",[23],{"facility":5,"status":24,"city":25,"state":25,"zip":26,"country":27,"countryCode":7,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Seoul","06351","South Korea",{"type":29,"coordinates":30},"Point",[31,32],126.9784,37.566,{"lat":32,"lon":31},[35],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":21},{"type":16,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Haeyoung Kim","Associate professor","100507943","prospective-cohort-for-tumor-bed-boost-radiotherapy-in-her2-positive-breast-cancer-100507943",false,"NCT05893966","Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer","BOOST-HER2","Inclusion Criteria:\n\n* Female patients with age minimum 19\n* Pathological confirmation of HER2+ invasive breast cancer\n* Eastern Cooperative Oncology Group performance status 0-2\n* Informed consent of the participant\n\nExclusion Criteria:\n\n* Pathological confirmation of ductal carcinoma in situ of the breast\n* Previous history of radiation therapy to ipsilateral breast","FEMALE","19 Years",{"count":49,"type":50},400,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery.\n\nThe main questions it aims to answer are:\n\n* 7-year ipsilateral breast tumor recurrence\n* 7-year disease-free survival\n* 7-year locoregional recurrence\n* 7-year overall survival\n* Adverse events of radiation therapy\n\nParticipants will be assessed by multi-dimensional methods after radiation therapy:\n\n* Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination\n* Assessment for the adverse events according to CTCAE version 5.0",[54],"Breast Cancer","2026-08-06",{"date":57,"type":58},"2026-08-10","ACTUAL",{"date":60,"type":58},"2022-11-29",{"date":62,"type":50},"2032-11-29",{"name":5,"class":6},1]